先声药业(02096.HK)与Ipsen就SIM0613签订独家授权许可协议 最高可收取10.6亿美元款项

Core Viewpoint - The agreement between Jiangsu Zaiming and Ipsen Pharma SAS allows Ipsen to obtain global exclusive rights for the development, production, and commercialization of the antibody-drug conjugate SIM0613, targeting LRRC15, outside Greater China, with potential financial benefits for the company totaling up to $1.06 billion [1][1][1] Financial Terms - The agreement includes an upfront payment of $45 million, along with milestone payments related to research, regulatory, and commercialization achievements, and tiered royalties on sales [1][1][1]